Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparison Between the Efficacy of Sodium-Glucose Co-transporter 2 Inhibitor Therapy Versus Angiotensin-converting Enzyme Inhibitor in the Treatment of Diabetic Kidney Disease

NCT05373004 is registered in ClinicalTrials.gov with Omar Tarek Elfarargi as lead sponsor.

NCT NCT05373004
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05373004 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparison Between the Efficacy of Sodium-Glucose Co-transporter 2 Inhibitor Therapy Versus Angiotensin-converting Enzyme Inhibitor in the Treatment of Diabetic Kidney Disease
Lead sponsor
Omar Tarek Elfarargi
Phase
Phase 2/3
Overall status
Unknown status
Start date
March 31, 2023
Completion date
May 31, 2024
Enrollment
212 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic nephropathy type 2